We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
8 own
14 watching
Current Price
$1.26
$-0.08
(-5.97%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
89.92M
52-Week High
8.6
52-Week Low
0.53
Average Volume
0.53M
Dividend Yield
--
P/E Ratio
--
Market Capitalization89.92M
52-Week High8.6
52-Week Low0.53
Average Volume0.53M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber s congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
15days ago
StockNews.com downgraded shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. Other equities analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of ProQR Therapeutics from an...
Zolmax
15days ago
StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) from a hold rating to a sell rating in a research report sent to investors on Friday. Other equities analysts have also issued reports about the company. Raymond James raised ProQR Therapeutics from a market perform rating to an...
Zolmax
3 months ago
Chardan Capital downgraded shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) from a buy rating to a neutral rating in a report released on Friday morning, MarketBeat reports. Other equities research analysts have also issued reports about the stock. StockNews.com upgraded shares of ProQR ...
Zolmax
8 months ago
Millennium Management LLC lifted its stake in shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) by 2,680.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 337,504 shares of the biopharmaceutical companys stock after ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.26
$-0.08
(-5.97%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00